Program
Etoposide
Also written as “etoposide”, “Etoposide (dose level 1)” and “Etoposide (dose level 2)”.
Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Large B-Cell, Diffuse · Lung Neoplasms · Ovarian Neoplasms, led by 20 companies.
Drug pageEtoposide: every studyMany companies study it; this page follows only the 28 they lead. All 598 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 41 open or running | phase 3since Dec 3, 2020 | Mar 12, 2018 | none ahead |
| Hoffmann-La Rocheits history only | 40 open or running | phase 3since Jul 19, 2019 | Oct 20, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 20 open or running | phase 2since Jan 7, 2021 | Feb 20, 2019 | none ahead |
| Jiangsu HengRui Medicineits history only | 20 open or running | phase 3since Jun 24, 2019 | Jun 24, 2019 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Nov 6, 2013 | Nov 6, 2013 | none ahead |
| BeOne Medicinesits history only | 10 open or running | phase 2since Feb 8, 2018 | Feb 8, 2018 | none ahead |
| BioNTechits history only | 11 open or running | phase 2since Jun 3, 2024 | Jun 3, 2024 | Jun 2027phase 2 · NCT06449209 |
| Boehringer Ingelheimits history only | 11 open or running | phase 3since Mar 4, 2026 | Mar 4, 2026 | Sep 9, 2028phase 3 · NCT07472517 |
| Eli Lillyits history only | 10 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| EpicentRxits history only | 10 open or running | phase 2since Jun 29, 2015 | Jun 29, 2015 | none ahead |
| Gilead Sciencesits history only | 10 open or running | phase 1since Nov 17, 2017 | Nov 17, 2017 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Aug 14, 2002 | Aug 14, 2002 | none ahead |
| Lederle Laboratoriesits history only | 10 open or running | phase 2since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Lee's Pharmaceuticalits history only | 10 open or running | phase 1since Apr 13, 2020 | Apr 13, 2020 | none ahead |
| Newsoara HYK Biopharmaceutical (Shanghai)its history only | 11 open or running | phase 2since Jul 2, 2025 | Jul 2, 2025 | Dec 2026phase 2 · NCT07136285 |
| Otsukaits history only | 10 open or running | phase 2since Jul 28, 2009 | Jul 28, 2009 | none ahead |
| Pfizerits history only | 10 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| Sanofi | 10 open or running | phase 2since Apr 18, 2006 | Apr 18, 2006 | none ahead |
| Swami Rama Cancer Hospital and Research Instituteits history only | 10 open or running | phase 3since Sep 10, 2013 | Sep 10, 2013 | none ahead |
| Texas Oncology Cancer Centerits history only | 10 open or running | phase 2since Nov 18, 2011 | Nov 18, 2011 | none ahead |
Also a collaborator on its studies: Genelux.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Apr 18, 2006First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT00315705 · 50 enrolled · United States
- Dec 9, 2016Named etoposideINNProposed as its International Nonproprietary Name in WHO's List 116
TargetBeta
“DNA topoisomerase II inhibitor”ChEMBL 37, by rule
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00315705Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States | 2 | Completed | May 2010 | 50 |
How it is read
Names in the registry
- “Etoposide”, 18 entries
- “etoposide”, 3 entries
- “Etoposide (dose level 1)”, 1 entry
- “Etoposide (dose level 2)”, 1 entry
- “recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 12 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lung Neoplasms, 2 studies
- Ovarian Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.